A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

CP-751,871

single dose, 1-hr IV infusion

BIOLOGICAL

CP-751,871

single dose, 1-hr IV infusion

BIOLOGICAL

CP-751,871, moxifloxacin, saline

Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion

Trial Locations (1)

Pfizer Investigational Site, New Haven